Clinical trials: Schizophrenia Spectrum Disorders
Schizophrenia, Schizoaffective Disorder
Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia
Withania somnifera (WSE; Ashwagandha in Ayurveda) extracts have been used as an adaptogen or to build resistance to stress or diseases in indigenous medical systems in India for centuries.
- Trial name
- NCT01793935
- Testing
- Sensoril®
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- K.N. Roy Chengappa
Schizophrenia, Schizoaffective Disorder
Cognitive-Behavioral Therapy in Veterans With Schizophrenia
This is a study comparing the benefits of two types of individual psychotherapy (cognitive-behavioral therapy for psychosis and supportive therapy) in symptomatic Veteran outpatients diagnosed with schizophrenia or…
- Trial name
- NCT00688259
- Testing
- Supportive Therapy (ST), Cognitive Behavioral Therapy for Psychosis (CBTp)
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Type 2 Diabetes Mellitus
Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
This proposal aims to use well-validated methodologies such as dual energy x-ray absorptiometry (DEXA), frequently sampled oral glucose tolerance tests (fsOGTTs), and hyperinsulinemic euglycemic clamps to characterize the…
- Trial name
- BMS (NCT00205660)
- Testing
- Stayers, Switchers
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia
6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)
A multicenter, randomized, parallel-group, double-blind, fixed dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in participants with an acute exacerbation of schizophrenia.
- Trial name
- NCT01098110
- Testing
- Asenapine 5 mg, Asenapine 10 mg
- Volunteers
- 532 people
- Sponsor
- Organon and Co
Bipolar Disorder, Alcoholism
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
The investigators will conduct a 12-week, randomized, double-blind, parallel-group, placebo-controlled study of aripiprazole in 132 persons with Alcohol Use Disorder (AUD) and bipolar I or II disorder, currently depressed or…
- Conditions
- Bipolar Disorder, Alcoholism, Alcohol Abuse
- Trial name
- NCT02918370
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Cognition
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of…
- Conditions
- Schizophrenia, Cognition, Psychosis
- Trial name
- NCT02104752
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Schizophrenia
A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot
This study will evaluate the safety, tolerability, efficacy and pharmacokinetics of aripiprazole intramuscular (IM) depot multiple doses every 4 weeks in adult patients with schizophrenia.
- Trial name
- NCT01870999
- Testing
- aripiprazole IM depot, aripiprazole tablets
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia
To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjunctive medication.
- Trial name
- NCT01829048
- Testing
- PF-02545920
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Schizophrenia
An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia
The purpose of this study is to determine whether aripiprazole injection into the shoulder or the buttocks produces similar effects in the body
- Trial name
- NCT01646827
- Testing
- Aripiprazole IM Depot
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychotic Disorders, Psychosis
Pilot Study of Motivational Interviewing for Loved Ones
The study population for this research will include parents and concerned significant others (PCSO) of individuals experiencing recent (past five years) onset of a psychotic disorder (hereafter referred to as individuals with…
- Conditions
- Psychotic Disorders, Psychosis, Psychotic Episode
- Trial name
- MILO-Pilot (NCT04010747)
- Testing
- Motivational Interviewing for Loved Ones (MILO), Mental Health Services Consultation and Waitlist
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Boston Medical Center
Schizophrenia
Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia
This study will compare the effectiveness of three treatments in improving medication adherence, symptoms, and function in people with schizophrenia.
- Trial name
- NCT00455663
- Testing
- Cognitive Adaptation Training, Pharm-Cognitive Adaptation Training, Treatment as usual
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 3831 in subjects with schizophrenia.
- Trial name
- NCT02873208
- Testing
- ALKS 3831
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 266 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo.
- Trial name
- NCT00549718
- Testing
- Lurasidone HCl
- Where
- 48 sites in United States, France and 5 more
- Volunteers
- 489 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
To compare the health outcome of patients with schizophrenia, who are at risk for relapse, when treated with a long acting injection form of olanzapine versus treatment with oral olanzapine.
- Trial name
- NCT00320489
- Testing
- olanzapine, olanzapine pamoate depot
- Where
- 49 sites in United States, Argentina and 10 more
- Volunteers
- 524 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia.
- Trial name
- NCT03437668
- Testing
- WSE
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Chengappa, K.N. Roy, MD
Schizophrenia, Schizoaffective Disorder
Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia
Investigating the effect of non-invasive transcranial current stimulation on auditory hallucinations in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Auditory Hallucinations
- Trial name
- NCT01963676
- Testing
- tDCS
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)
Clozapine (CLZ) is the most effective antipsychotic for treatment-refractory schizophrenia (SZ). Despite the overwhelming evidence of superior efficacy, CLZ is infrequently prescribed in the US, at a considerably lower rate than…
- Trial name
- BEN (NCT02404155)
- Testing
- Clozapine
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- University of Maryland, Baltimore
Psychotic Disorders, Mood Disorders
Reproductive Life Planning for Women With Mental Illness
Women represent the fastest growing population within the VHA. Many are of reproductive age and experience mental health concerns.
- Conditions
- Psychotic Disorders, Mood Disorders, Stress Disorders, Post-Traumatic
- Trial name
- RLP-MH (NCT03969589)
- Testing
- Reproductive Life Planning-Mental Health (RLP-MH) Intervention, Written Materials on Reproductive Life Planning
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development